DeepMed Research

Aspartic acid

Generic Name: Aspartic acid

Brand Names: Aminosyn II 7 %, Sulfite-free, Aminosyn-PF 7%, Clinisol 15, Olimel, Periolimel, Plenamine, Premasol, Primene, Prosol, Trophamine 10 %

Drug Type: Small Molecule

Chemical Formula: C_₄H_₇NO_₄

CAS Number: 56-84-8

Unique Ingredient Identifier: 30KYC7MIAI

Background: One of the non-essential amino acids commonly occurring in the L-form. It is found in animals and plants, especially in sugar cane and sugar beets. It may be a neurotransmitter.

Indication: There is no support for the claim that aspartates are exercise performance enhancers, i.e. ergogenic aids.

Associated Therapies: Amino acid supplementation

Clinical Trials

Efficacy and Safety of Ultrasonic Ablation to Treat Secondary Hyperparathyroidism in Chronic Kidney Disease Patients

Not Applicable

Completed

Conditions: Disorders of Parathyroid Gland
Hyperparathyroidism

Interventions: Procedure: Ultrasonic ablation
Procedure: Parathyroidectomy
Drug: Active vitamin D

First Posted Date: 2012-07-13

Last Posted Date: 2016-10-17

Lead Sponsor: Dongliang Zhang, MD

Target Recruit Count: 79

Registration Number: NCT01640184

Locations: 🇨🇳
Beijing Chao-Yang Hospital, Beijing, Beijing, China
🇨🇳
Beijing Friendship Hospital, Beijing, Beijing, China

The Effect of Deliberate Hypotension on QTc, Tp-e Intervals and Heart Rate Variability

Phase 4

Completed

Conditions: Mandibular Prognathism
Mandibular Retrognathism

Interventions: Drug: Group R
Drug: Group D
Drug: Group N

First Posted Date: 2012-07-06

Last Posted Date: 2019-03-19

Lead Sponsor: Yonsei University

Target Recruit Count: 66

Registration Number: NCT01634594

Locations: 🇰🇷
Young Jun Oh, Seoul, Korea, Republic of

Migalastat Food Effect Study

Phase 1

Completed

Conditions: Fabry Disease

Interventions: Drug: A (migalastat)
Drug: B (migalastat)
Drug: C (migalastat)
Drug: D (migalastat)
Drug: E (migalastat)

First Posted Date: 2011-12-12

Last Posted Date: 2013-12-18

Lead Sponsor: Amicus Therapeutics

Target Recruit Count: 20

Registration Number: NCT01489995

Locations: 🇺🇸
GSK Investigational Site, Austin, Texas, United States

Add Vitamin D With Standard of Care for Chronic Hepatitis C Patients

Phase 4

Completed

Conditions: Chronic Hepatitis C

Interventions: Drug: Vit D

First Posted Date: 2011-09-23

Last Posted Date: 2023-03-06

Lead Sponsor: Hanyang University

Target Recruit Count: 180

Registration Number: NCT01439776

Locations: 🇰🇷
HANYANG University Guri Hospital, Guri, Gyeonggido, Korea, Republic of
🇰🇷
BORAMAE Medical Center, Seoul, Korea, Republic of
🇰🇷
Sooncunhayng University Hospital Seoul, Seoul, Korea, Republic of

and more 10 locations

Healthy Volunteer Pilot Study Using 3 Types of Modified Release Formulations of Firategrast to Investigate How Quickly Absorption From the Digestive System Takes Place.

Phase 1

Completed

Conditions: Multiple Sclerosis, Relapsing-Remitting

Interventions: Drug: B
Drug: C
Drug: D
Drug: A

First Posted Date: 2011-08-29

Last Posted Date: 2017-06-20

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 20

Registration Number: NCT01424462

Locations: 🇦🇺
GSK Investigational Site, Randwick, New South Wales, Australia

Vitamin D and Glucose Metabolism in Pediatrics

Phase 4

Conditions: Insulin Resistance
Obesity
Vitamin D25 Insufficiency

Interventions: Drug: Vitamin D drops
Drug: Placebo drops

First Posted Date: 2011-07-01

Last Posted Date: 2011-07-01

Lead Sponsor: Weill Medical College of Cornell University

Target Recruit Count: 110

Registration Number: NCT01386736

Locations: 🇺🇸
Weill Cornell Medical College, New York, New York, United States

A Study to Determine the Pharmacodynamics of LX4211 Relative to Meals in Healthy Subjects

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Schedule A
Drug: Schedule B
Drug: Schedule C
Drug: Schedule D
Drug: Schedule E

First Posted Date: 2011-04-13

Last Posted Date: 2011-05-19

Lead Sponsor: Lexicon Pharmaceuticals

Target Recruit Count: 14

Registration Number: NCT01334242

Locations: 🇺🇸
Lexicon Investigational Site, San Antonio, Texas, United States

Evaluation of the Influence of Food Regimen on Oshadi D Absorption

Not Applicable

Completed

Conditions: Lupus Erythematosus, Systemic

Interventions: Drug: Oshadi D

First Posted Date: 2011-04-01

Last Posted Date: 2012-06-21

Lead Sponsor: Oshadi Drug Administration

Target Recruit Count: 8

Registration Number: NCT01327352

Locations: 🇮🇱
Assaf Harofe Medical Center,, Zrifin, Israel

This Study Is To Estimate The Time Course Of Pf-04764793 In The Blood Following Dosing By Oral Inhalation From Dry Powder Inhalers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Treatment F
Drug: Treatment C
Drug: Treatment D
Drug: Treatment A
Drug: Treatment B
Drug: Treatment G
Drug: Treatment E

First Posted Date: 2011-01-07

Last Posted Date: 2018-12-03

Lead Sponsor: Pfizer

Target Recruit Count: 48

Registration Number: NCT01272375

Locations: 🇸🇬
Pfizer Investigational Site, Singapore, Singapore

Safety, Pharmacodynamics, and Pharmacokinetics of Different Dosing Regimens of MK-8266 in Participants With Hypertension (MK-8266-008)

Phase 1

Completed

Conditions: Hypertension

Interventions: Drug: Treatment D
Drug: Treatment A
Drug: Treatment B
Drug: Treatment E
Drug: Treatment F
Drug: Treatment C

First Posted Date: 2010-11-19

Last Posted Date: 2019-02-28

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 31

Registration Number: NCT01244035

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy